ACVRL1 Drug Discovery Landscape & Assay Solutions

Market Intelligence, Clinical Progress, and High-Purity Reagents for HHT, Angiogenesis, and Vascular Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for ACVRL1 drug discovery. Select your modality below:

Live ACVRL1 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

• ➤ View Active Clinical Trials
• ➤ Latest Resistance Research
• ➤ Recent Patent Filings

Global Clinical Landscape & Future Outlook

The therapeutic targeting of ACVRL1 (ALK1) has pivoted from oncology angiogenesis inhibition toward Hereditary Hemorrhagic Telangiectasia (HHT), where the market sees urgent unmet need. Following Pfizer's discontinuation of the ALK1-Fc fusion (PF-06946828) in oncology, Merck's pulocimab (anti-ALK1 mAb) and Santen's sevabertinib (oral ALK1 inhibitor) now lead the HHT pipeline. The race is intensifying around selective BMP9/BMP10 blockade without disrupting physiological TGF-β signaling. As a critical receptor for endothelial cell function and angiogenesis, ACVRL1 is also targeted to bypass VEGF-resistance in solid tumors and to modulate aberrant vascular networks in HHT. As first-generation therapies reach the clinic, the next wave of R&D is focusing on highly localized, conditionally active molecules that avoid systemic endothelial toxicities, including subcutaneous delivery formulations and tissue-specific penetration (particularly mucosal and hepatic AVMs). The emerging ophthalmology segment (wet AMD) represents a parallel growth vector, requiring distinct assay paradigms for retinal endothelial selectivity.

Competitive Modality & Indication Snapshot

Molecular Differentiation & Assay Strategy

ACVRL1 (ALK1) is a type I receptor of the TGF-β superfamily containing an N-terminal GS domain and a C-terminal serine/threonine protein kinase domain (UniProt P37023). Key mutations associated with HHT2 include dbSNP rs149664056 and variants that lead to loss of receptor activity in response to BMP9 (e.g., retained in the endoplasmic reticulum). Developing selective therapeutics requires high-quality reagents that preserve native conformation and glycosylation.

Core Assay Challenges:

1. Affinity Tuning for Bispecifics: Moderate affinity for ACVRL1 is preferred to avoid target-mediated drug disposition (TMDD) in normal tissues. Use multi-concentration SPR/BLI with correctly folded ACVRL1 ECD.
2. Selectivity vs ALK2/ALK5: High homology in kinase and ECD domains demands a cross-screening panel. TarMart provides ACVRL1, ACVR1, and TGFBR1 ECD-Fc proteins with mass spec verification.
3. Ligand Blockade Mechanism: Need to assess neutralization of BMP9/BMP10 binding, receptor internalization, or heteromeric complex formation with ENG. Competitive ELISA and flow cytometry assays are recommended.
4. pH Stability & Internalization: For antibody-based therapies, pH-dependent binding (endosomal pH 5.5) must be tested to avoid rapid release. TarMart's native glycosylated proteins ensure accurate in vitro-in vivo correlation.

TarMart Solution:

• HEK293 Expression: Ensures native glycosylation critical for BMP9/10 binding. All proteins >95% purity, endotoxin <1 EU/µg.
• Lentivirus System: Full-length ORF for stable cell lines overcoming limitations of primary endothelial cell passaging.
• Pathological Mutant Proteins: Pre-emptively store mutant ACVRL1 (e.g., R78H, L43P) for small molecule rescue assays in HHT2 models.

TarMart Product Portfolio Rationale

• ECD Truncation: Met1-Pro118 fragment excludes transmembrane region, retains BMP9 binding site, ensures >95% monomer purity for SPR chip immobilization.
• Mutant Protein Reserve: Include HHT2-associated mutations for pathway reactivation studies.
• Ternary Complex Support: Provide ENG and BMP9 proteins for ACVRL1-ENG-BMP9 complex assembly (cell-free EM studies).

Related Targets (Cross-Selling Pathway Partners)